Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Oct 2021 01:19 PM
RNS
PDMR Shareholding/Share Incentive Plan
01 Oct 2021 12:32 PM
RNS
Holding(s) in Company
28 Sep 2021 07:00 AM
RNS
Purchase/Transfer of Shares and PDMR Shareholdings
21 Sep 2021 07:00 AM
RNS
Nominated as finalists for Health Tech Awards 2021
14 Sep 2021 07:00 AM
RNS
Half-year Report
13 Sep 2021 07:00 AM
RNS
DXRX Platform Contract Win
08 Sep 2021 07:00 AM
RNS
Two new experts join the Diaceutics Advisory Panel
01 Sep 2021 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
31 Aug 2021 07:00 AM
RNS
Notice of Investor Presentation
30 Jul 2021 04:54 PM
RNS
PDMR Shareholding/Share Incentive Plan
08 Jul 2021 07:00 AM
RNS
Trading Update
01 Jul 2021 07:00 AM
RNS
Issue of Share Options and PDMR Shareholdings
29 Jun 2021 04:56 PM
RNS
PDMR Shareholding/Share Incentive Plan
24 Jun 2021 07:00 AM
RNS
New Contract Wins
18 Jun 2021 07:00 AM
RNS
Purchase of Shares and PDMR Shareholding
16 Jun 2021 07:00 AM
RNS
Capital Markets Day and KPI Update
07 Jun 2021 06:23 PM
RNS
PDMR Shareholding/Share Incentive Plan
07 Jun 2021 07:00 AM
RNS
Notice of Capital Markets Day
04 Jun 2021 07:00 AM
RNS
Presenting data on COVID impact on cancer at ASCO
21 May 2021 01:49 PM
RNS
Holding(s) in Company
21 May 2021 07:00 AM
RNS
Change of Adviser
19 May 2021 03:24 PM
RNS
Result of AGM
13 May 2021 07:00 AM
RNS
LGC SeraCare Partnership
12 May 2021 05:58 PM
RNS
Sale of Shares and PDMR Shareholding
05 May 2021 06:03 PM
RNS
Holding(s) in Company
04 May 2021 03:11 PM
RNS
Sale of Shares and Director/PDMR Shareholding
30 Apr 2021 11:01 AM
RNS
Share Incentive Plan
21 Apr 2021 07:00 AM
RNS
Notice of AGM and posting of Annual Report
12 Apr 2021 07:00 AM
RNS
New Vice President of Operations in Asia
08 Apr 2021 09:49 AM
RNS
Transfer of Shares and Director/PDMR Shareholding
07 Apr 2021 07:58 AM
RNS
Transfer of Shares and Director/PDMR Shareholding
06 Apr 2021 11:12 AM
RNS
Issue of Share Options/PDMR Shareholdings
01 Apr 2021 07:00 AM
RNS
COVID-19 Testing Data licensing agreement
30 Mar 2021 07:00 AM
RNS
New lease agreement and related party transaction
15 Mar 2021 07:00 AM
RNS
Final Results
08 Mar 2021 07:00 AM
RNS
Notice of Results
04 Mar 2021 12:49 PM
RNS
New Vice President of Finance appointment
21 Jan 2021 07:00 AM
RNS
Quarterly media update
11 Jan 2021 09:56 AM
RNS
Holding(s) in Company
11 Jan 2021 07:00 AM
RNS
Trading update
22 Dec 2020 07:01 AM
RNS
Directorate Change
22 Dec 2020 07:00 AM
RNS
Directorate Change
10 Dec 2020 03:10 PM
RNS
Holding(s) in Company
17 Nov 2020 07:00 AM
RNS
European international award win
10 Nov 2020 04:32 PM
RNS
Holding(s) in Company
28 Oct 2020 07:00 AM
RNS
Commercial launch of DXRX
07 Sep 2020 02:05 PM
RNS
Second Price Monitoring Extn
07 Sep 2020 02:00 PM
RNS
Price Monitoring Extension
07 Sep 2020 11:00 AM
RNS
Price Monitoring Extension
07 Sep 2020 07:00 AM
RNS
Half-year Report

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100

Latest directors dealings